Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKalman, J.-
dc.contributor.authorSanders, P.-
dc.contributor.authorRosso, R.-
dc.contributor.authorCalkins, H.-
dc.identifier.citationCirculation, 2017; 136(5):490-499-
dc.descriptionOriginally published July 31, 2017-
dc.description.abstractSince the original description of atrial fibrillation ablation, numerous studies have demonstrated the superiority of catheter ablation over pharmacological therapy for maintenance of sinus rhythm in patients with both paroxysmal and persistent atrial fibrillation. However, to date, no randomized studies have been powered to demonstrate a mortality or stroke reduction benefit of rhythm control with catheter ablation over a rate control strategy. The results of such ongoing studies are not expected until 2018 or 2019. Thus, the only indication for atrial fibrillation ablation in recent guidelines has been the presence of symptoms. However, up to 40% of an atrial fibrillation population may be asymptomatic. In 2017, in the absence of randomized studies, are there nevertheless data that support atrial fibrillation ablation in asymptomatic patients?-
dc.description.statementofresponsibilityJonathan M. Kalman, Prashanthan Sanders, Raphael Rosso, Hugh Calkins-
dc.publisherAmerican Heart Association-
dc.rights© 2017 American Heart Association, Inc.-
dc.subjectAtrial Fibrillation-
dc.subjectCatheter Ablation-
dc.titleShould we perform catheter ablation for asymptomatic atrial fibrillation?-
dc.typeJournal article-
dc.identifier.orcidSanders, P. [0000-0003-3803-8429]-
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.